Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.

Authors

Sunil Verma

Tom Baker Cancer Centre, Calgary, AB, Canada

Sunil Verma , Joyce O'Shaughnessy , Howard A. Burris III, Mario Campone , Emilio Alba , David Chandiwana , Stephanie Manson , Santosh C. Sutradhar , Mauricio Monaco , Wolfgang Janni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.

First Author: Michelino DeLaurentiis

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.

First Author: Joyce O'Shaughnessy

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.

First Author: Wolfgang Janni

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).

First Author: Gabriel N. Hortobagyi